Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of point-of-care anti-BCMA CAR T-cell therapy GLPG5301 in relapsed/refractory multiple myeloma
NL-OMON60620Phase 2Completed
- Sponsor
- Lakefront Biotherapeutics
- Start
- Feb 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of GLPG5301 in multiple myeloma (MM) (2 arms), sponsored by Lakefront Biotherapeutics. Primary endpoints: Incidence of adverse events, serious adverse events, and dose-limiting toxicities and Objective response. Started Feb 2023; status: completed.
02
Drugs
GLPG5301
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60620.